{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056977","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.464252+00:00","generated_at":"2026-06-02T06:18:09.483113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Crinetics Q1 net loss $66.9M; paltusotine NDA on track for 2H 2024","bullets":["Net loss of $66.9M in Q1 2024 vs $46.0M in Q1 2023; revenue fell to $0.6M from $2.7M.","Cash, equivalents, and investments total $901.0M as of March 31, 2024, partly from $350M private placement in Feb.","Paltusotine PATHFNDR-2 Phase 3 met primary and all secondary endpoints; NDA submission expected in 2H 2024.","Initial atumelnant Phase 2 results in CAH and Cushing's to be presented at ENDO 2024 (June 1-4).","Plan to initiate paltusotine Phase 3 in carcinoid syndrome by end of 2024 pending FDA discussions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056977","json":"https://secwatch.observer/filing/0000950170-24-056977.json","markdown":"https://secwatch.observer/filing/0000950170-24-056977.md","text":"https://secwatch.observer/filing/0000950170-24-056977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/0000950170-24-056977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/crnx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:18:09.483113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50f4b7fe7c0785512161372bfcf2548355a33e25","claim":"Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million, net income $66.9 million.","evidence_excerpt":"of $5.6 million. • Net loss for the three months ended March 31, 2024, was $66.9 million, compared to a net loss of $46.0 million for the same period in 2023. • Revenues were$0.6 million for the three months ended March 31, 2024, compared to $2.7 million for the same period in 2023. Revenues were derived from licensing arrangements for our paltusotine product","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024056977/0000950170-24-056977-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.6 million"},{"label":"Net income","value":"$66.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}